SLC5A2 and thyroid cancer: This study found no increased rate of thyroid cancer in T2DM patients taking GLP‐1‐RAs versus SGLT2‐Is, but an imprecise increased rate in CWM patients taking GLP‐1‐RAs versus two different comparator weight management drugs (Figure 3).